Trichomoniasis is a sexually transmitted infection caused by a single-celled parasite called Trichomonas vaginalis, and it ranks as the most common nonviral STI in the world. Global estimates put the number of new cases at roughly 156 million per year, yet it receives a fraction of the public attention given to chlamydia or gonorrhea. The infection is curable with antibiotics, but left untreated it can cause reproductive complications and raise the risk of acquiring HIV. What makes trichomoniasis especially tricky is that most people who carry it have no symptoms at all, which lets it circulate silently through sexual networks.
The Parasite Behind the Infection
Trichomonas vaginalis is not a bacterium or a virus. It is a protozoan, a tiny single-celled organism with whip-like flagella that propel it through the mucous membranes of the urogenital tract. Unlike many STI pathogens, it lives outside of host cells, clinging to the surface of vaginal or urethral epithelial tissue rather than burrowing inside. Once attached, the parasite damages tissue in several ways: it kills host cells on contact, disrupts the normal microbial environment of the vagina, and triggers an inflammatory immune response.1Cell Press (Trends in Parasitology). New insights into Trichomonas vaginalis host-parasite interactions
One detail that most people never hear about is that many T. vaginalis parasites carry their own passengers: small RNA viruses called Trichomonasviruses that live inside the parasite itself.2PubMed Central. Trichomonas vaginalis infection in symbiosis with Trichomonasvirus and Mycoplasma Research has shown that human epithelial cells can actually sense these endosymbiotic viruses through immune receptors, which ramps up inflammatory signaling and may partly explain why trichomoniasis is linked to preterm birth and increased HIV susceptibility.3PLOS ONE. Endobiont Viruses Sensed by the Human Host – Beyond Conventional Antiparasitic Therapy In other words, the damage from trichomoniasis is not just about the parasite itself; the viruses hitching a ride inside it appear to make the immune reaction worse.
How Common Is Trichomoniasis
Despite flying under the radar in public health messaging, trichomoniasis is staggeringly common. The World Health Organization’s most recent prevalence estimates put the global rate at about 5.3% in women and 0.6% in men.4PubMed Central. Trichomoniasis In the United States alone, an estimated 2.6 million people aged 15 to 59 were carrying an active infection in 2018, with roughly 6.9 million new infections occurring that year.5PubMed Central. Incidence and Prevalence of Trichomonas vaginalis Infection Among Persons Aged 15 to 59 Years: United States, 2018
The burden is not distributed evenly. U.S. survey data show that infection is associated with older age, lower educational attainment, lower socioeconomic status, and having multiple sexual partners. The racial disparity is stark: among Black women and men in the U.S., prevalence was about 6.8%, compared with 0.4% among other racial and ethnic groups.4PubMed Central. Trichomoniasis Researchers attribute these gaps not to biology but to structural inequities in healthcare access and the concentration of infection within sexual networks where screening and treatment are less available.
Unlike chlamydia and gonorrhea, which peak among younger adults, trichomoniasis prevalence and incidence actually increase with age in both sexes.5PubMed Central. Incidence and Prevalence of Trichomonas vaginalis Infection Among Persons Aged 15 to 59 Years: United States, 2018 People aged 15 to 24 accounted for only about 16% of all prevalent infections. This age pattern surprises many clinicians who are used to thinking of STIs as a problem mostly for teenagers and young adults.
Symptoms in Women and Men
The majority of trichomoniasis cases produce no symptoms at all, which is why the infection spreads so efficiently. When symptoms do appear in women, the most common complaints are abnormal vaginal discharge, itching, and vulvovaginal burning. Clinical exams often reveal redness and discharge, sometimes with a frothy, yellowish-green appearance and an unpleasant odor.6PubMed. Trichomonas vaginalis is very rare among women with vaginal discharge in Podlaskie province, Poland Some women also experience pain during urination or intercourse. The classic textbook description of “strawberry cervix,” a speckled reddening of the cervical surface, shows up in only a minority of cases and usually requires magnification to see.
In men, trichomoniasis has traditionally been considered a mild or self-limiting nuisance, but that framing understates the problem. Men with trichomoniasis are significantly more likely to have urethral discharge and inflammatory cells in their urethral secretions compared with uninfected men, even after accounting for other STIs. In one study, the parasite remained independently associated with nongonococcal, nonchlamydial urethritis after adjusting for multiple confounders.7PubMed. Clinical manifestations of trichomoniasis in men Symptoms can include a clear or whitish drip from the penis, mild irritation or burning after urination, and occasionally discomfort during ejaculation. Many men clear the infection on their own within weeks, but during that window they remain contagious and can reinfect partners.
Why Trichomoniasis Is More Dangerous Than It Sounds
Because it often causes only mild or absent symptoms, trichomoniasis has historically been dismissed as a low-stakes STI. The evidence paints a different picture.
HIV Acquisition
One of the most consequential complications is an elevated risk of acquiring HIV. The parasite damages the protective epithelial barrier of the genital tract, triggers local inflammation that draws in immune cells (the very cells HIV targets), and is frequently found alongside bacterial vaginosis, which independently increases HIV susceptibility.8PubMed Central. Trichomonas vaginalis and HIV infection acquisition: a systematic review and meta-analysis Each of those mechanisms stacks the odds against the infected person. In regions with high HIV prevalence, treating trichomoniasis aggressively has become part of the broader HIV prevention strategy.
Pelvic Inflammatory Disease and Fertility
Among women with suspected pelvic inflammatory disease, those who also had trichomoniasis were roughly twice as likely to have endometritis, an inflammation of the uterine lining. Persistent endometritis was still present in over half of participants a month after treatment and was more common among women who had tested positive for trichomoniasis at baseline. Infertility and recurrent pelvic inflammatory disease were also more frequent in infected women, while rates of pregnancy and live birth were lower.9Sexually Transmitted Infections. Trichomonas vaginalis, endometritis and sequelae among women with clinically suspected pelvic inflammatory disease
Pregnancy Complications
Trichomoniasis during pregnancy carries real risks. A systematic review and meta-analysis found that infection was associated with a higher odds of preterm delivery, pre-labor rupture of membranes, and low birth weight.10PubMed Central. Trichomoniasis and adverse birth outcomes: a systematic review and meta-analysis Earlier population-level data had already established these links, with trichomoniasis at mid-gestation significantly associated with all three outcomes after controlling for other risk factors.11PubMed. Trichomonas vaginalis associated with low birth weight and preterm delivery
Here is where things get complicated, though. A large randomized trial found that treating asymptomatic trichomoniasis in pregnancy with metronidazole actually increased the rate of preterm delivery rather than preventing it. Women who received metronidazole delivered preterm at nearly twice the rate of those who received a placebo.12PubMed. Failure of metronidazole to prevent preterm delivery among pregnant women with asymptomatic Trichomonas vaginalis infection One hypothesis is that killing the parasite releases inflammatory debris (possibly including those endosymbiotic viruses mentioned earlier) that triggers preterm labor. This finding has made the management of trichomoniasis during pregnancy a nuanced clinical judgment rather than a straightforward “treat immediately” decision, especially for asymptomatic women.
The Vaginal Microbiome Connection
Trichomoniasis does not exist in isolation. The infection has a tangled relationship with bacterial vaginosis, a condition where the vagina’s protective lactobacilli are replaced by a more diverse mix of anaerobic bacteria. Women with bacterial vaginosis are at substantially higher risk of acquiring trichomoniasis. A meta-analysis and individual studies have confirmed that the association is strong: women with bacterial vaginosis had more than double the risk of picking up a trichomoniasis infection compared with women whose vaginal flora was healthy.13PubMed Central. Bacterial vaginosis and the risk of Trichomonas vaginalis acquisition among HIV-1 negative women
The mechanism runs in both directions. Lactobacillus species produce lactic acid, hydrogen peroxide, and antimicrobial substances that help keep pathogens in check. When these bacteria are diminished, the cervicovaginal environment loses its natural defenses. Bacteria commonly found in bacterial vaginosis produce enzymes that damage genital tissue and undermine innate immunity, making it easier for T. vaginalis to establish itself.14PubMed Central. Bacterial Vaginosis and Its Association With Incident Trichomonas vaginalis Infections: A Systematic Review and Meta-Analysis Conversely, trichomoniasis itself disrupts the vaginal microbiome, further depleting lactobacilli and encouraging the overgrowth of anaerobic species.15PubMed Central. Associations between bacterial vaginosis, candida vaginitis, trichomonas vaginalis, and vaginal pathogenic community in Chinese women The result is a feedback loop: bacterial vaginosis makes trichomoniasis more likely, and trichomoniasis makes bacterial vaginosis worse.
How Trichomoniasis Is Diagnosed
For decades the standard diagnostic test was wet mount microscopy: a clinician places a drop of vaginal fluid on a slide and looks for the motile, pear-shaped parasites under a microscope. The problem is that wet mount misses a lot of infections. The parasites have to be alive and swimming for the test to work, so any delay in getting the sample to the microscope reduces sensitivity considerably.
Nucleic acid amplification tests, which detect the parasite’s genetic material rather than the organism itself, are far more accurate. One head-to-head comparison found that a transcription-mediated amplification assay was significantly more sensitive than either wet mount or culture for diagnosing trichomoniasis in women.16PubMed. Comparison of APTIMA Trichomonas vaginalis transcription-mediated amplification to wet mount microscopy, culture, and polymerase chain reaction for diagnosis of trichomoniasis in men and women These molecular tests can be run on vaginal swabs or urine samples, and they have become the gold standard in settings where they are available. The downside is cost and turnaround time, which can take days depending on the lab.
Point-of-care rapid antigen tests offer a middle ground. These immunochromatographic tests detect parasite membrane proteins and return results in minutes, much like a rapid COVID antigen test. They are user-friendly and can be run in a clinic without laboratory equipment.17PubMed. Performance of rapid immunochromatographic assay in the diagnosis of Trichomoniasis vaginalis However, their diagnostic accuracy is not as well established as molecular testing, and a meta-analysis noted that uncertainty remains about their sensitivity and specificity.18PubMed. Diagnostic Accuracy of Rapid Antigen Tests for Trichomoniasis: A Meta-Analysis In practice, a negative rapid test in a person with symptoms may warrant follow-up with a molecular test.
One important gap: routine STI screening panels in many clinics do not include trichomoniasis by default. If you are being tested for chlamydia and gonorrhea, do not assume that trichomoniasis is part of the panel. You often have to ask for it specifically.
Treatment and the Single-Dose Debate
Trichomoniasis is treated with nitroimidazole antibiotics, primarily metronidazole or tinidazole. For years, the standard recommendation for women was a single 2-gram oral dose of metronidazole, chosen for its convenience. A randomized controlled trial changed that thinking. Women assigned to a 7-day course of 500 mg metronidazole twice daily were significantly less likely to test positive at follow-up than women given the single dose, with about 11% still positive in the multi-dose group versus 19% in the single-dose group.19The Lancet Infectious Diseases. Single-dose versus 7-day-dose metronidazole for the treatment of trichomoniasis in women: an open-label, randomised controlled trial
The advantage of multi-dose treatment was even more pronounced in women who had symptoms at the time of diagnosis, those with a history of prior trichomoniasis infections, and those who also had bacterial vaginosis. In these subgroups, the single dose failed at roughly twice the rate of the 7-day course.20PubMed Central. A Comparison of Single versus Multi-Dose Metronidazole by Select Clinical Factors for the Treatment of Trichomonas vaginalis in Women Current U.S. guidelines now recommend the 7-day regimen as the preferred treatment for women. For men, the single 2-gram dose is still considered adequate because the infection tends to reside in a less sheltered anatomical environment.
Metronidazole resistance exists but is relatively uncommon. When standard treatment fails, clinicians typically escalate to higher doses of metronidazole or switch to tinidazole, which can overcome some forms of low-level resistance.21PubMed Central. Treatment of infections caused by metronidazole-resistant Trichomonas vaginalis Truly refractory cases are rare but can be difficult to manage, sometimes requiring prolonged high-dose courses or experimental approaches.
The Metronidazole and Alcohol Warning
If you are prescribed metronidazole, you will almost certainly be told to avoid alcohol during treatment and for at least 24 to 48 hours afterward. The concern is a disulfiram-like reaction: nausea, vomiting, flushing, abdominal cramping, and a rapid heartbeat triggered by the drug’s interference with how your body metabolizes alcohol. A case report documented this reaction occurring not from drinking but from a liquid medication that contained alcohol as an inactive ingredient, which the clinical team initially failed to identify as the culprit.22PubMed Central. Disulfiram-like Reaction With Metronidazole: An Unsuspected Culprit The practical lesson: check the ingredient lists of any other medications, mouthwashes, or liquid supplements you are using while taking metronidazole, not just your drinking habits.
Retesting and Reinfection
Getting treated once does not end the story. Reinfection is extremely common with trichomoniasis, largely because sexual partners are often not treated simultaneously. Current guidelines recommend that all sexual partners be treated at the same time, ideally before the couple resumes sexual contact.
After completing treatment, retesting is recommended to confirm the infection has cleared. But timing matters. Because nucleic acid amplification tests are so sensitive, they can detect residual genetic material from dead parasites for weeks after treatment. Testing too early produces a false positive. For women who received the 7-day metronidazole course, retesting should occur no earlier than three weeks after finishing treatment. For those who received a single dose, the wait should be at least four weeks.23PubMed Central. Optimal timing for Trichomonas vaginalis test of cure using nucleic acid amplification testing Testing before those windows risks picking up parasite DNA that no longer represents a live infection, leading to unnecessary retreatment.
Even with proper timing, a positive retest does not always mean treatment failed. It may mean you were reinfected by an untreated partner. Distinguishing treatment failure from reinfection is clinically challenging, but the management approach is similar: retreatment, often with a longer or higher-dose regimen, and renewed emphasis on partner treatment.
Why Trichomoniasis Gets So Little Attention
Given that trichomoniasis is the most prevalent nonviral STI globally and carries meaningful health consequences, the relative silence around it is puzzling. Several factors contribute. It is not a nationally reportable condition in the United States, unlike chlamydia, gonorrhea, and syphilis, so surveillance data are limited and policymakers tend to focus resources elsewhere. Many standard STI panels do not test for it. The parasite disproportionately affects populations that already face barriers to healthcare access. And the infection’s reputation as a minor annoyance, rather than a serious health threat, has been hard to shake despite mounting evidence to the contrary.
Screening recommendations remain inconsistent. Some professional organizations recommend annual screening for women at high risk, while others leave the decision to clinical judgment. In men, routine screening is not widely recommended at all, which means male partners often go undiagnosed and serve as a reservoir for reinfection. The result is a self-perpetuating cycle: low testing leads to low detection, which leads to low perceived prevalence, which leads to continued low testing. Researchers have argued that incorporating trichomoniasis into standard STI panels would be a relatively inexpensive way to break this cycle and reduce downstream complications, particularly HIV transmission in high-prevalence settings.
The Endosymbiotic Virus Angle
The discovery that many T. vaginalis parasites harbor their own internal viruses has opened a genuinely novel line of research. These Trichomonasviruses are double-stranded RNA viruses that live inside the parasite’s cytoplasm. They do not infect human cells directly, but human immune cells recognize them through toll-like receptor 3, a sensor normally tuned to detect viral infections. When these viral particles are released during parasite death, they trigger an inflammatory cascade involving interferons and other signaling molecules.3PLOS ONE. Endobiont Viruses Sensed by the Human Host – Beyond Conventional Antiparasitic Therapy
This matters practically because metronidazole treatment, while killing the parasite, also releases these viral particles into the surrounding tissue, potentially amplifying the very inflammation it is supposed to resolve. The same study found that metronidazole treatment intensified the proinflammatory response in vitro. This finding may help explain the paradox observed in the pregnancy trial where treating asymptomatic trichomoniasis increased preterm delivery rates. It also raises a provocative question about future treatment strategies: could therapies that target both the parasite and its endosymbiotic viruses produce better outcomes? No such dual-target therapy exists yet, but the concept represents a shift in how researchers think about trichomoniasis treatment, not just as a simple “kill the bug” problem, but as a more complex host-parasite-virus interaction that demands finesse.